Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | KMT2A fusion |
Therapy | MI-503 |
Indication/Tumor Type | acute myeloid leukemia |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
KMT2A fusion | acute myeloid leukemia | predicted - sensitive | MI-503 | Preclinical - Cell culture | Actionable | In a preclinical study, MI-503 inhibited growth of several acute myeloid leukemia (AML) cell lines and primary AML samples harboring KMT2A (MLL) fusions in culture (PMID: 25817203). | 25817203 |
PubMed Id | Reference Title | Details |
---|---|---|
(25817203) | Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo. | Full reference... |